FDA clears IND for AnGes and Vasomune’s AV-001 in severe burn resuscitation

AnGes Inc. said the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application for Pegevongitide (AV-001), a Tie2 receptor agonist it is jointly developing with Vasomune Therapeutics, Inc., for acute-phase resuscitation treatment in patients with severe burns. The company said the IND clearance allows initiation of a clinical program to evaluate AV-001’s safety and efficacy in severely burned patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnGes Inc. published the original content used to generate this news brief on March 05, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.